Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 35.5 USD -0.28%
Market Cap: 3.2B USD

Wall Street
Price Targets

TVTX Price Targets Summary
Travere Therapeutics Inc

Wall Street analysts forecast TVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TVTX is 42.33 USD with a low forecast of 31.31 USD and a high forecast of 51.45 USD.

Lowest
Price Target
31.31 USD
12% Downside
Average
Price Target
42.33 USD
19% Upside
Highest
Price Target
51.45 USD
45% Upside
Travere Therapeutics Inc Competitors:
Price Targets
300142
Walvax Biotechnology Co Ltd
41% Downside
ARQT
Arcutis Biotherapeutics Inc
7% Upside
PHARM
Pharming Group NV
31% Upside
ACLX
Arcellx Inc
79% Upside
CCCC
C4 Therapeutics Inc
419% Upside
ZBIO
Zenas Biopharma Inc
191% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
5% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
33% Upside

Revenue
Forecast

Revenue Estimate
Travere Therapeutics Inc

The compound annual growth rate of Travere Therapeutics Inc's revenue for the next 4 years is 46%.

N/A
Past Growth
46%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-48%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TVTX's stock price target?
Price Target
42.33 USD

According to Wall Street analysts, the average 1-year price target for TVTX is 42.33 USD with a low forecast of 31.31 USD and a high forecast of 51.45 USD.

What is Travere Therapeutics Inc's Revenue forecast?
Projected CAGR
46%

The compound annual growth rate of Travere Therapeutics Inc's revenue for the next 4 years is 46%.

Back to Top